Eccogene
Clinical trials sponsored by Eccogene, explained in plain language.
-
New drug combo targets fatty liver in major trial
Disease control Recruiting nowThis study tests two experimental drugs, ECC4703 and ECC0509, alone or together, in 160 adults with MASH (a type of fatty liver disease). The goal is to see if they can safely reduce liver fat over 12 weeks. Participants will be randomly assigned to receive the drugs or a placebo…
Phase: PHASE2 • Sponsor: Eccogene • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Healthy volunteers needed to test new fatty liver drug with and without food
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called ECC4703, being developed for a serious fatty liver condition (MASH). Researchers want to see how taking the drug with or without food changes the amount that gets into the blood. 72 healthy adults will receive a single dose of the dr…
Phase: PHASE1 • Sponsor: Eccogene • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC